The company focuses on developing low-cost therapeutic alternatives for the treatment of anaphylaxis, asthma, COPD, and allergic rhinitis. It also has a biotechnology pipeline that includes a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer. The company's products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI Injection for acute allergic reactions, ZIMHI Injection for opioid overdose, Tempol for COVID-19, and a Beclomethasone metered dose inhaler product candidate for COVID-19 treatment.